Quick Decision Guide
Before choosing a hospital or arranging international travel, consider these questions:
| Question | Why it matters |
|---|---|
| What exactly is the blood cancer diagnosis? | Treatment options differ substantially between diseases |
| Is the disease newly diagnosed, relapsed, or refractory? | Previous response and disease status can change the treatment pathway |
| What treatments have already been used? | Prior therapy can affect eligibility for subsequent treatment |
| Are molecular or genetic tests available? | Some treatments depend on specific biological features |
| Is CAR-T being considered? | Eligibility depends on disease type, target, prior therapy, and other factors |
| Is a clinical trial being considered? | Each trial has its own inclusion and exclusion criteria |
| Is the patient medically stable enough for international travel? | Travel and treatment timing can be critical in rapidly progressing disease |
The goal is not to find the "best hospital" in general.
The goal is to identify a center and treatment pathway that may fit the patient's specific situation.
What Blood Cancers Can Be Treated in China?
Chinese hematology and oncology centers treat a broad range of malignant blood disorders.
Acute Lymphoblastic Leukemia (ALL)
ALL treatment can involve chemotherapy, targeted therapies, immunotherapy, stem-cell transplantation, andβwhere appropriateβcellular therapies such as CAR-T. For patients with relapsed or refractory disease, the treatment discussion may become substantially different.
Acute Myeloid Leukemia (AML)
AML is a biologically diverse disease. Treatment decisions may depend on cytogenetic and molecular findings, disease risk, age, general health, and previous treatment response. For relapsed or refractory AML, clinical trials may become particularly relevant.
Chronic Lymphocytic Leukemia (CLL)
CLL differs substantially from acute leukemias. Some patients may initially be monitored rather than treated, while others may require targeted or systemic therapy. The treatment pathway should be determined by disease status rather than by diagnosis alone.
Chronic Myeloid Leukemia (CML)
CML is commonly managed using targeted therapies directed at the BCR::ABL1 pathway. Reviewing the current molecular response and treatment history is particularly important before considering a change in treatment strategy.
Lymphoma
Lymphomas include numerous distinct diseases including DLBCL, other non-Hodgkin lymphomas, Hodgkin lymphoma, T-cell lymphomas, and other B-cell malignancies. The treatment approach can vary considerably between lymphoma subtypes.
Multiple Myeloma
Multiple myeloma is a plasma-cell malignancy in which treatment decisions depend on disease characteristics, prior lines of therapy, response, and overall clinical status. BCMA-directed cellular therapies, including CAR-T, have become an important area of treatment and clinical research.
Why Do International Patients Consider China for Blood Cancer Treatment?
Specialized Hematology Centers
Major academic and oncology institutions with dedicated hematology, transplantation, and cellular-therapy programs
Cellular Therapy Experience
Substantial clinical and research activity in CAR-T and other cellular therapies, particularly in hematologic malignancies
Clinical Trials
Clinical studies involving cellular therapies, targeted therapies, immunotherapies, transplantation, and other investigational approaches
Access to Selected Advanced Therapies
Treatment pathways not readily accessible in some home countries
Different Treatment Costs
Costs can differ substantially between countries β but there is no reliable single figure. Costs depend on diagnosis, treatment type, hospital, and many other factors.
CAR-T Cell Therapy for Blood Cancer in China
CAR-T is not one treatment, and it is not appropriate for every blood cancer patient.
Eligibility can depend on:
- Exact diagnosis
- Disease subtype
- Target antigen
- Age
- Previous treatments
- Response to previous treatment
- Current disease status
- Organ function
- General health
- Treatment-specific criteria
The key question is therefore not:
"Can I get CAR-T in China?"
It is:
"Is there a CAR-T strategy targeting the biology of my disease, and do I meet the eligibility criteria?"
Approved Treatment vs Clinical Trial
One of the most important distinctions for international patients.
β Approved
A treatment has received regulatory approval for a defined disease, indication, and patient population.
π§ͺ Clinical Trial
The treatment or treatment strategy is being evaluated under a research protocol with defined inclusion/exclusion criteria.
π¬ Investigational
The treatment may still be in an early stage of clinical development, with important questions about safety, efficacy, or appropriate patient selection still being studied.
"Advanced" does not automatically mean "better."
A newer or experimental therapy may be appropriate for some patients and inappropriate for others.
Before traveling, confirm:
- β’ Regulatory status
- β’ Exact indication
- β’ Eligibility requirements
- β’ Treatment protocol
- β’ Hospital or trial acceptance
- β’ Expected costs
- β’ Follow-up requirements
When Might Advanced Treatment Be Worth Exploring?
Advanced treatment or clinical-trial pathways may be worth discussing with a specialist when a patient:
β When to consider
- Has relapsed disease
- Has refractory disease
- Has progressed after multiple lines of therapy
- Has a specific biomarker or molecular target
- Is being evaluated for CAR-T
- May qualify for a clinical trial
- Has limited standard treatment options
β When treatment in China may not be the right path
- The proposed treatment does not match the diagnosis
- The required biomarker or target is absent
- The patient does not meet clinical-trial criteria
- The patient's condition requires urgent treatment
- The patient's general health makes travel or treatment unsafe
- The proposed therapy is experimental when an established option is more appropriate
- Required post-treatment monitoring cannot be arranged
These factors do not establish eligibility by themselves.
A specialist must review the patient's medical history and current clinical information.
What Medical Information Is Needed for an Initial Review?
Diagnosis
- β’ Pathology report
- β’ Bone marrow biopsy report
- β’ Flow cytometry / Immunophenotyping
- β’ Cytogenetic results
- β’ Relevant pathology slides or blocks
Molecular and Genetic Testing
- β’ Molecular testing
- β’ FISH
- β’ PCR / NGS
- β’ Relevant biomarkers
Previous Treatment
- β’ Treatment names and dates
- β’ Number of treatment lines
- β’ Response and relapse/progression
- β’ Reason for discontinuation
- β’ Previous transplant or cellular therapy
Current Disease Status
- β’ Recent blood counts
- β’ Bone marrow assessment
- β’ PET/CT or other imaging
- β’ Disease-response assessment
- β’ Recent clinical notes
Can You Get a Second Opinion From China Before Traveling?
In some situations, Chinese hospitals or specialist centers can review medical records remotely or provide an initial online consultation.
This may help determine:
- β’ Whether the diagnosis and current disease status are sufficiently documented
- β’ Whether additional testing may be needed
- β’ Whether a particular treatment pathway may be worth evaluating
- β’ Whether CAR-T or another cellular therapy may be relevant
- β’ Whether a clinical trial may be worth investigating
- β’ Whether an in-person assessment is required
How Does Access to Blood Cancer Treatment in China Work?
International treatment generally begins with medical recordsβnot with a flight booking.
Prepare the medical record
Collect diagnosis, pathology, imaging, laboratory results, molecular testing, and treatment history.
Initial review
The case is reviewed to identify potentially relevant treatment pathways or specialist centers.
Hospital evaluation
The selected center determines whether the available information is sufficient and whether additional testing is required.
Eligibility assessment
If CAR-T, transplantation, or a clinical trial is being considered, the patient is assessed against the relevant criteria.
Confirm the treatment pathway
Before travel, confirm the hospital's acceptance, expected treatment plan, timing, and estimated costs.
Treatment and follow-up
Treatment duration, hospitalization, monitoring, and follow-up vary substantially by disease and treatment.
How Much Does Blood Cancer Treatment Cost in China?
There is no single price for treating blood cancer in China. Costs may vary significantly depending on:
- β’ Standard systemic therapy
- β’ Targeted therapy
- β’ Immunotherapy
- β’ Stem-cell transplantation
- β’ CAR-T or other cellular therapy
- β’ Clinical-trial treatment
Treatment cost is not the same as total treatment-journey cost.
A low advertised treatment price may not represent the actual amount a patient ultimately spends.
Total cost may also include:
- β Flights
- β Accommodation
- β Local transportation
- β Companion expenses
- β Translation or administrative services
- β Follow-up travel
How Should You Choose a Blood Cancer Center in China?
Instead of asking:
"What is the best blood cancer hospital in China?"
ask:
"Which center has the most relevant expertise for this specific disease and treatment pathway?"
Disease-Specific Expertise
Does the center routinely treat the specific leukemia, lymphoma, or myeloma?
Cellular Therapy Capability
If CAR-T is relevant, does the center have an established program or an appropriate clinical trial?
Transplant Program
For patients where transplantation is being considered, evaluate the center's relevant transplantation capabilities.
Clinical Research
Are there active trials relevant to the patient's diagnosis and biomarker profile?
Molecular Diagnostics
Can the center perform or appropriately interpret the testing needed to guide treatment?
International Patient Support
Can the hospital communicate with international patients and coordinate the required medical documentation?
Transparency
Can the center clearly explain: treatment status, eligibility, expected timeline, estimated costs, and follow-up requirements?
Questions to Ask a Chinese Hospital Before Traveling
- Is the proposed treatment approved for this exact diagnosis and indication?
- If not, is it being offered through a clinical trial?
- What are the eligibility requirements?
- What medical records and tests are required?
- Are additional molecular or biomarker tests needed?
- Can the case be reviewed before travel?
- How long does the evaluation normally take?
- How long might the patient need to remain in China?
- What does the quoted price include?
- What costs are excluded?
- What complications could create additional costs?
- What follow-up will be required after returning home?
- What happens if the treatment does not work?
- What alternative pathways are available if the patient is not eligible?
What Can Be Determined Before Travel?
Before traveling, it may be possible to clarify:
- β Whether the diagnosis appears compatible with a particular treatment pathway
- β Which type of specialist center may be relevant
- β Whether CAR-T or another advanced therapy is worth investigating
- β Whether clinical trials may be relevant
- β What records may be required
- β What questions should be asked of the hospital
But some questions cannot be answered reliably without a specialist review:
- β Final treatment eligibility
- β Final hospital acceptance
- β Individual prognosis
- β Whether an experimental treatment is appropriate
- β Whether international travel is medically safe
Your Next Decision
If you are considering blood cancer treatment in China, do not start by choosing a hospital.
Start with three questions:
1. What exactly is the diagnosis?
2. What has already been tried?
3. What treatment or access pathway is now being considered?
Once these are clear, it becomes much easier to determine whether China, another country, a standard treatment pathway, a clinical trial, CAR-T, transplantation, or another option deserves further evaluation.
Explore the Decision
Continue your research with these related resources.
π©Έ Blood Cancer Hub
Overview of blood cancer types and treatment pathways.
Explore β𧬠CAR-T Therapy
Technical comparison of CD19, BCMA, CD22, and dual-target CAR-T.
Explore therapies βπ¨π³ China Cancer Care Hub
Deep dive into China's CAR-T network, hospitals, and clinical trials.
Explore China βπ§ͺ Clinical Trials
Search current clinical trials by cancer, biomarker, treatment and location.
Search trials βBlood Cancer Treatment in China: Frequently Asked Questions
China may be worth considering for some international patients because of its specialized hematology centers, cellular-therapy programs, transplantation capabilities, and clinical research. Whether it is appropriate depends on the individual disease and treatment pathway.
Chinese hospitals treat different forms of leukemia, including ALL, AML, CLL, and CML. Treatment options vary substantially by disease subtype and patient status.
CAR-T therapies are available in China for selected hematologic malignancies, alongside ongoing clinical research into additional targets and indications. Eligibility depends on the specific treatment and patient.
No. CAR-T eligibility depends on factors such as disease type, target antigen, prior treatment, disease status, age, health status, and treatment-specific criteria.
Both situations can exist. Some CAR-T products have regulatory approval for specific indications, while other CAR-T strategies remain under clinical investigation. The exact regulatory status must be checked for the specific disease and product.
Yes. Chinese research centers conduct clinical trials across leukemia, lymphoma, multiple myeloma, cellular therapy, targeted therapy, immunotherapy, and other areas. Individual eligibility must be assessed against each trial's protocol.
There is no universal price. Costs depend on diagnosis, treatment, hospital, medication, cellular therapy, transplantation, clinical-trial status, hospitalization, testing, and complications.
Some hospitals can provide remote medical-record review or online consultation before an international patient travels. This does not guarantee treatment acceptance.
Generally, it is safer to obtain an initial evaluation and confirm hospital acceptance and treatment planning before arranging international travel.
A useful package may include the pathology or bone marrow report, diagnosis, treatment history, recent laboratory results, imaging, molecular testing, and a summary of the patient's current condition.
Medical Information Update
Last reviewed: August 2026
Information about regulatory approvals, clinical trials, treatment availability, costs, and hospital programs can change over time. For high-stakes treatment decisions, current information should be verified with the treating institution and relevant regulatory or clinical sources.
CancerCareE is an independent patient information and introduction platform. It is not a hospital, clinic, physician, or direct treatment provider.
The information on this page is educational and does not constitute a diagnosis, treatment recommendation, medical guarantee, or confirmation of eligibility for any treatment or clinical trial.
Do not book international travel or begin treatment based on this page alone. Final eligibility, treatment planning, and medical decisions must be confirmed by qualified medical professionals.
Need Help Navigating Blood Cancer Treatment Options in China?
Submit your case for a free, confidential assessment. Our team can help you understand whether China, a clinical trial, CAR-T, or another pathway may be worth evaluating for your specific situation.
Free β’ Confidential β’ 48-Hour Response β’ No Obligation